Barbara K. Finck - 31 Dec 2022 Form 5 Insider Report for Comera Life Sciences Holdings, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 31 Dec 2022
Net transaction value: $0
SEC form: 5
Accepted by SEC: 14 Feb 2023, 16:53:02 UTC
Prior SEC filing: 02 Jun 2022
Next SEC filing: 14 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact

Key filing fact

Barbara K. Finck filed Form 5 for Comera Life Sciences Holdings, Inc. on 14 Feb 2023.

Key facts

This page summarizes Barbara K. Finck's Form 5 filing for Comera Life Sciences Holdings, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Feb 2023, 16:53.

Change

Previous filing in this sequence was filed on 02 Jun 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 5 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMRA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +37,111
Change %
Price
Shares after: 37,111
Date: 19 May 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,111
Exercise price: $0.5900
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Barbara K. Finck is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 2 footnotes

Footnote F1

The shares underlying the option vest in 44 equal monthly installments beginning on June 8, 2021.

Footnote F2

This option was issued pursuant to the terms of a business combination agreement involving the issuer and Comera Life Sciences, Inc. in exchange for a comparable option previously issued by such company.